Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial

Frailty is increasing in prevalence. Because patients with frailty are often perceived to have a less favorable risk/benefit profile, they may be less likely to receive new pharmacologic treatments. We investigated the efficacy and tolerability of dapagliflozin according to frailty status in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Jawad H., Jhund, Pardeep S., Belohlávek, Jan, de Boer, Rudolf A., Chiang, Chern-En, Desai, Akshai S., Drożdż, Jarosław, Hernandez, Adrian F., Inzucchi, Silvio E., Katova, Tzvetana, Kitakaze, Masafumi, Kosiborod, Mikhail N., Lam, Carolyn S.P., Maria Langkilde, Anna, Lindholm, Daniel, Bachus, Erasmus, Martinez, Felipe, Merkely, Béla, Petersson, Magnus, Saraiva, Jose F. Kerr, Shah, Sanjiv J., Vaduganathan, Muthiah, Vardeny, Orly, Wilderäng, Ulrica, Claggett, Brian L., Solomon, Scott D., McMurray, John J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815819/
https://www.ncbi.nlm.nih.gov/pubmed/36029465
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.061754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815819/
https://www.ncbi.nlm.nih.gov/pubmed/36029465
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.061754

Ejemplares similares